A phase I study of oral uracil/ftorafur (UFT) plus leukovorin in combination with weekly paclitaxel (P) in patients (pts) with solid tumors.

被引：0
|
作者：
Mayer, F
von Pawel, J
Beck, J
Schroeder, M
Hartmann, JT
Kanz, L
Bokemeyer, C
机构：
[1] St Johannes Hosp, Duisburg, Germany
[2] Univ Mainz, D-6500 Mainz, Germany
[3] Asklepios Fachklin Munchen Gauling, Munich, Germany
[4] Univ Tubingen, Med Ctr, Dept Hematol Oncol, Tubingen, Germany
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
620P
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [21] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Calvo, Emiliano
    Sessa, Cristiana
    Harada, Guilherme
    de Miguel, Maria
    Kahatt, Carmen
    Luepke-Estefan, Xarles Erik
    Siguero, Mariano
    Fernandez-Teruel, Carlos
    Cullell-Young, Martin
    Stathis, Anastasios
    Drilon, Alexander
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1263 - 1273
  • [22] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Emiliano Calvo
    Cristiana Sessa
    Guilherme Harada
    Maria de Miguel
    Carmen Kahatt
    Xarles Erik Luepke-Estefan
    Mariano Siguero
    Carlos Fernandez-Teruel
    Martin Cullell-Young
    Anastasios Stathis
    Alexander Drilon
    Investigational New Drugs, 2022, 40 : 1263 - 1273
  • [23] Pemetrexed in combination with paclitaxel: A phase I clinical and pharmacokinetic trial in patients with solid tumors.
    Graefe, T.
    Bolling, C.
    Lubbing, C.
    Latz, J.
    Blatter, J.
    Hanauske, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
  • [24] A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors.
    Papadopoulos, K
    Mendelson, D
    Preston, GG
    Lopez, AM
    Ricart, AD
    Schwartz, G
    Needle, MN
    Gordon, MS
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9116S - 9116S
  • [25] Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors
    Lokich, J
    CANCER, 2000, 89 (11) : 2309 - 2314
  • [26] Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors.
    Moore, DJ
    Bahrani, A
    Hwang, JJ
    Ramzi, P
    Marshall, JL
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (02) : S391 - S391
  • [27] Phase I/II study of weekly paclitaxel (P), UFT and leucovorin in patients with metastatic breast cancer
    Chang, AY
    Beith, J
    Yeo, W
    Boyer, M
    Wong, J
    Lim, SE
    Chan, AT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S
  • [28] Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Elisabeth I. Heath
    George R. Blumenschein
    Roger B. Cohen
    Patricia M. LoRusso
    Noelle K. LoConte
    Sindy T. Kim
    Ana Ruiz-Garcia
    Richard C. Chao
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 703 - 712
  • [29] Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Heath, Elisabeth I.
    Blumenschein, George R., Jr.
    Cohen, Roger B.
    LoRusso, Patricia M.
    LoConte, Noelle K.
    Kim, Sindy T.
    Ruiz-Garcia, Ana
    Chao, Richard C.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) : 703 - 712
  • [30] A phase I clinical study of the sequential administration of paclitaxel (P) followed by oral topotecan (T) and etoposide (E) in patients with solid tumors.
    Lima, CMSR
    Catapano, CV
    Sherman, CA
    Mushtaq, CM
    Pacheco, D
    Harper, M
    Lightcap, KD
    Fields, SZ
    Green, MR
    CLINICAL CANCER RESEARCH, 1999, 5 : 3798S - 3798S
12345